PD184352 (CI-1040)

Catalog No.S1020

PD184352 (CI-1040) Chemical Structure

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 45 Publications

13 Customer Reviews

  • The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

    Science 2011 331, 912-916. PD184352 (CI-1040) purchased from Selleck.

     

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

  •  

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

    LY294002 (10 μM for 12 h)- and PD184352 (10 μM for 12 h)-treated Her2-transfected DU145 and PC3 cells, respectively, showed reciprocal feedback inhibition between the PI3K/AKT and MEK/ERK path ways

    Proc Natl Acad Sci U S A 2011 108, 16392-7. PD184352 (CI-1040) purchased from Selleck.

  • a Expression and phosphorylation status of AKT and ERK1/2 and amount of cleaved CPP32 at 72 h after drug treatment were assessed by western blot. Actin was used to confirm equal protein loading. A representative experiment of three was reported. The panel shows cropped blots.

    J Hematol Oncol, 2017, 10(1):19. PD184352 (CI-1040) purchased from Selleck.

    The effect of CI-1040 on cell viability of molecular apocrine lines. MTT assay to measure cell viability in MDA-MB-453 cell line after treatment with CI-1040 (CI) at 2 to 25 μM concentrations. MTT assay to measure cell viability in HCC-1954 cell line after treatment with CI-1040 at 2 to 25 μM concentrations.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

  • Combination indices (CI) for flutamide (FLU) and CI-1040 combination therapy in MDA-MB-453-R line using MTT assay. Therapies were carried out with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM (CI-5 and CL-10). The concentrations of fluatmide and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2SEM. Western blot analysis was used to measure the phosphorylated and total ERK levels in MDA-MB-453-R line following combination therapies with CI-1040 (5 μM)/flutamide (5 μM) and CI-1040 (5 μM)/flutamide (10 μM). RR values were measured relative to the untreated MDA-MB-453-R line.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

    Western blot analysis to measure the phosphorylated and total ERK levels in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (CI) at 10-μM concentration.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • Relative expression of AR using RT-PCR in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (MEK Inh) at 10-μMconcentration for 24 hours. Expression is relative to that of vehicle-treated cells (CTL). *P < .01 is for CI-1040 versus control. Error bars,±2 SEMs.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

    Synergistic effect of AR and mitogen-activated protein kinase kinase inhibitors on cell viability. (A) MTT assay to measure cell viability in MDA-MB-453 cell line after monotherapies and combination treatments with flutamide (FLU) and CI-1040 (CI) at 5 and 10 μΜ concentrations. CTL: control. Error bars: ±2 SEM. (B) Combination indices (CI) for flutamide and CI-1040 combination therapy in MDA-MB-453 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM. The concentrations of FLU and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2 SEM. (C) Combination indices for flutamide and CI-1040 combination therapy in HCC-1954 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 20 and 40 μM with each concentration of CI-1040 at 5 and 10 μM. (D) Combination indices for flutamide and CI-1040 combination therapy in HCC-202 cell line using MTT assay at concentrations described in Figure 2C.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

  • The bar chart represents the relative numbers of third-round colonies of primary hematopoietic cells transduced with MLL-AF9 with treatment of compound PD184352 (CI-1040, 10 μM, a MEK inhibitor) and SB216763 (10 μM, GSK-3 inhibitor). The synergic effect between compounds CI-1040 and SB-216763 has been observed.

     

     

    2010 Dr. Shuo Dong of Baylor College of Medicine. PD184352 (CI-1040) purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.
Features First MEK inhibitor to begin clinical development.
Targets
MEK1 [1]
(Cell-free assay)
MEK2 [1]
(Cell-free assay)
17 nM 17 nM
In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. [1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. [2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. [3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H9 NHrSUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i5OGlEPTB;MD6wNlI4PiEQvF2= NXPRRYJPW0GQR1XS
CHP-212 NX;SdIpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm3Xm5RUUN3ME2wMlAzQDh3IN88US=> NF[xbFdUSU6JRWK=
EoL-1-cell NWi0OZNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnI[nFKSzVyPUCuNFQyPTJizszN M4fDRnNCVkeHUh?=
DU-4475 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLaTWM2OD1yLkC3OVk6KM7:TR?= NUT5b5dsW0GQR1XS
MMAC-SF M1vzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTZeYZKSzVyPUCuNVA6PzRizszN NIDocndUSU6JRWK=
AGS MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;nTWM2OD1yLkGxO|E{KM7:TR?= M3vwWHNCVkeHUh?=
M14 Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnJWlhKSzVyPUCuNVU1PjhizszN MUDTRW5ITVJ?
CP50-MEL-B M1zWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDTTWM2OD1yLkG3NlU1KM7:TR?= M1q5SXNCVkeHUh?=
C32 NUXp[nZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjDTYxrUUN3ME2wMlE6ODd{IN88US=> NYXRZXo1W0GQR1XS
KMOE-2 NHfzdppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMUm3PVUh|ryP MXTTRW5ITVJ?
A101D Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHp[HlKSzVyPUCuNlE1KM7:TR?= NHfvWFdUSU6JRWK=
KM12 NWf3UVlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMkSwOVch|ryP M2HxTHNCVkeHUh?=
HSC-4 Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjyTWM2OD1yLkK0N|k2KM7:TR?= NInZVmNUSU6JRWK=
NOMO-1 MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[zW2lEPTB;MD6yOVc1OiEQvF2= Mn\nV2FPT0WU
MZ7-mel NXnVPJVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfkU5NKUUN3ME2wMlI3OzRizszN MUfTRW5ITVJ?
ACN MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrtN5BKSzVyPUCuNlY4OzdizszN MonGV2FPT0WU
MEL-HO NHPVeJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMke2OVIh|ryP NXHMOZgyW0GQR1XS
BHT-101 NGrscVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7RcnNOUUN3ME2wMlI5PjB4IN88US=> NHX1eYRUSU6JRWK=
SK-MEL-28 M4TtbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTDTWM2OD1yLkOwOFA6KM7:TR?= MmTpV2FPT0WU
KG-1 NGrse5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHZSWNbUUN3ME2wMlMxPjZ6IN88US=> M3PYdnNCVkeHUh?=
COLO-679 NGH6[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e3TWlEPTB;MD6zNlczKM7:TR?= MXfTRW5ITVJ?
SK-MEL-24 M33WOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwM{K4NVMh|ryP MmW4V2FPT0WU
G-361 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTGZ4xKSzVyPUCuN|Y4QTVizszN MkDZV2FPT0WU
KY821 MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\WUlBKSzVyPUCuN|c6OSEQvF2= MVXTRW5ITVJ?
KASUMI-1 MnLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDlepNsUUN3ME2wMlM6QSEQvF2= M17SV3NCVkeHUh?=
HL-60 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXHVpVKSzVyPUCuOFEyODdizszN NFS2WlFUSU6JRWK=
K5 NHfQTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwNEOxNVch|ryP MlzNV2FPT0WU
KU812 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEO2OXZKSzVyPUCuOFUzQTlizszN MXHTRW5ITVJ?
SH-4 MlzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwNE[yOVYh|ryP MXvTRW5ITVJ?
HTC-C3 NGX0bXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX5cmFJUUN3ME2wMlQ3PTNzIN88US=> MorlV2FPT0WU
CP66-MEL MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrCZ45KSzVyPUCuOFg5ODlizszN M2rxNHNCVkeHUh?=
WM-115 MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwNEmyOVch|ryP Mn7nV2FPT0WU
A2780 M{H1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfQVW5KSzVyPUCuOFk5OjNizszN M2T5dnNCVkeHUh?=
P12-ICHIKAWA MmDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwNkGyNlEh|ryP NVi4Z2txW0GQR1XS
HMV-II MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrTS2FxUUN3ME2wMlY1PDZ3IN88US=> M3Xac3NCVkeHUh?=
HT-144 Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfjU4lwUUN3ME2wMlY1PjV5IN88US=> M{jtZ3NCVkeHUh?=
LB2518-MEL MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwN{G2N|Ih|ryP MVPTRW5ITVJ?
NCI-SNU-1 M3vrVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELXV5JKSzVyPUCuO|U1OzNizszN NW\C[2ZPW0GQR1XS
C2BBe1 NXrXVVBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzVeItKSzVyPUCuPFExOjNizszN NXrKeoFJW0GQR1XS
PSN1 M1;ie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vxbmlEPTB;MD65OlE6PiEQvF2= MWPTRW5ITVJ?
UACC-257 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{G1b2lEPTB;MD65OlQ4OyEQvF2= MoKyV2FPT0WU
RVH-421 Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwOUexPEDPxE1? MljRV2FPT0WU
GP5d M4TDNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofDTWM2OD1yLkm4N|A5KM7:TR?= MmnPV2FPT0WU
TYK-nu NFvXWIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXftPGV2UUN3ME2xMlA{OTd{IN88US=> NVqweZZVW0GQR1XS
SK-N-AS NFzaN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHJ[JdKSzVyPUGuNFc6PDdizszN MXrTRW5ITVJ?
SW620 NIC5VGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTFwMUO1N|Qh|ryP MV;TRW5ITVJ?
HuP-T4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfITWM2OD1zLkG4N|U6KM7:TR?= NFfkcGZUSU6JRWK=
A549 MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTFwMUm1O|Yh|ryP MoTTV2FPT0WU
Mewo NGrGUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1u5VmlEPTB;MT6yNFI4PiEQvF2= M176NHNCVkeHUh?=
ONS-76 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFKxcWVKSzVyPUGuNlIxPDlizszN NF\Pc2dUSU6JRWK=
SK-MEL-1 M2DZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDETWM2OD1zLkKzOFE6KM7:TR?= MUDTRW5ITVJ?
RCM-1 MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\yeGZKSzVyPUGuNlQxPDdizszN MoXhV2FPT0WU
H-EMC-SS MkDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFwMkm2NFgh|ryP M2XDbXNCVkeHUh?=
NCI-H2291 NFLt[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonNTWM2OD1zLkOyOVM3KM7:TR?= M2\yWnNCVkeHUh?=
SW1463 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfXTWM2OD1zLkOzO|IyKM7:TR?= MW\TRW5ITVJ?
LS-411N NFHadVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XGOGlEPTB;MT60NFUyPyEQvF2= NXrVTGFoW0GQR1XS
BV-173 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFwNESwNVUh|ryP NYDGWJNFW0GQR1XS
LS-513 M{C4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPL[2xKSzVyPUGuOFUyQTJizszN Mn3DV2FPT0WU
LoVo NFvPcIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFwNE[zPVkh|ryP MY\TRW5ITVJ?
HO-1-N-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n5TGlEPTB;MT61NVY{PCEQvF2= MULTRW5ITVJ?
ML-2 NVjkVZJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTFwNUK4Olgh|ryP M2XYR3NCVkeHUh?=
NCI-H1437 NInNSWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTFwNUWyO|Uh|ryP MU\TRW5ITVJ?
SW1116 MlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXz6WldvUUN3ME2xMlU3Ozl6IN88US=> NEfT[mFUSU6JRWK=
A4-Fuk M2PUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fCcmlEPTB;MT61O|A1PSEQvF2= MoTyV2FPT0WU
HD-MY-Z M3TLTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFwNUezO|Yh|ryP NV;LSI1jW0GQR1XS
SK-MEL-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXt[GZKSzVyPUGuOVc1PTlizszN NVLpVFQ1W0GQR1XS
RT-112 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\NS|QyUUN3ME2xMlU5QTV{IN88US=> NYjIXWpSW0GQR1XS
COLO-829 NYXJeppoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHSTWM2OD1zLk[yNlMzKM7:TR?= MlzBV2FPT0WU
OVCAR-5 NHHGXlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfYTWM2OD1zLke3Olg4KM7:TR?= MXjTRW5ITVJ?
NB69 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7mTWM2OD1zLke4OFY6KM7:TR?= M4jtU3NCVkeHUh?=
NCI-H292 NImwWm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTFTWM2OD1zLki2Olk6KM7:TR?= MlTYV2FPT0WU
LOXIMVI M4nZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorlTWM2OD1zLki5OFI4KM7:TR?= MkLEV2FPT0WU
BPH-1 Ml3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTv[YVKSzVyPUGuPFk2QTFizszN MmfaV2FPT0WU
A375 NFv0cFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTFwOEm3NVQh|ryP M{D6enNCVkeHUh?=
LCLC-97TM1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLPTYVKSzVyPUGuPVIzPTZizszN M4DZdnNCVkeHUh?=
RXF393 M3TFWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTFwOUe4PFch|ryP NUHYV5BsW0GQR1XS
HCC70 M4fnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;wT2lEPTB;Mj6wNlQzPiEQvF2= NH;RXm1USU6JRWK=
EM-2 M4\OUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTGN5JHUUN3ME2yMlA4OTl6IN88US=> M3L1[XNCVkeHUh?=
MZ2-MEL NGm0bJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvHTWM2OD1{LkGxNVI4KM7:TR?= NFPuUoJUSU6JRWK=
HN NWrmV5dMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn6wTWM2OD1{LkG2Nlc5KM7:TR?= Ml\yV2FPT0WU
A2058 M2PNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEW0[HFKSzVyPUKuNVkzPzlizszN MorHV2FPT0WU
NB7 NY\VU|g2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJwM{SwPFYh|ryP M3TUTHNCVkeHUh?=
DOK NGnVd4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJwM{W3O|Mh|ryP M2fyfXNCVkeHUh?=
CAL-27 NYrvN4NvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEH4ZZBKSzVyPUKuN|kzOzZizszN MorCV2FPT0WU
BB65-RCC NV[3fnpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPGTWM2OD1{LkSwOlc1KM7:TR?= M4XLNnNCVkeHUh?=
RD M4jafWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;EWIhKSzVyPUKuOFQ4OjNizszN NVLvXYJHW0GQR1XS
KNS-62 M{[zSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFP4fXlKSzVyPUKuOVEyPjRizszN MmD1V2FPT0WU
EW-13 Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTJwNU[zN|kh|ryP NGfkPGxUSU6JRWK=
DB NFHUNpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zkPWlEPTB;Mj61PFc5QCEQvF2= NIXq[5FUSU6JRWK=
HCC2218 MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonQTWM2OD1{Lk[0O|c5KM7:TR?= Mm\VV2FPT0WU
L-363 Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJwN{SzO{DPxE1? NUe3d2t6W0GQR1XS
CHL-1 NUPtUIpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHH2d|VKSzVyPUKuPFA4QDVizszN MW\TRW5ITVJ?
BFTC-905 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrVWlJKSzVyPUKuPFI2OyEQvF2= NXe1Tlc1W0GQR1XS
HCE-T MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\3OoYxUUN3ME2yMlg{OjZ2IN88US=> M1fxSnNCVkeHUh?=
COLO-792 MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPJS4g2UUN3ME2yMlg1ODJ5IN88US=> NGDpe21USU6JRWK=
LB2241-RCC M1;RRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfvWpJKSzVyPUKuPFU5QTNizszN MlLMV2FPT0WU
CAL-39 M1XIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjTNmFKSzVyPUKuPFk6QTlizszN NYLSR3E1W0GQR1XS
T-24 M3vscGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHMXGpKSzVyPUKuPVEyOTJizszN Mk\QV2FPT0WU
NCI-H727 M17LPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHuyN2tKSzVyPUKuPVE4QTZizszN MXnTRW5ITVJ?
Ca9-22 M4Xlbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLHO3h1UUN3ME2yMlk4OjV3IN88US=> NW\HUG1jW0GQR1XS
MIA-PaCa-2 MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\5TWM2OD1|LkCwO|gyKM7:TR?= MXLTRW5ITVJ?
HT-1080 NFXBN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3FTWM2OD1|LkCxPVk4KM7:TR?= NIrLcm1USU6JRWK=
D-423MG MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zxR2lEPTB;Mz6wO|c2OyEQvF2= MkHrV2FPT0WU
LAMA-84 NVnlRXo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTNwMUO1PEDPxE1? NXOwTY57W0GQR1XS
SW780 MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;UTWM2OD1|LkG0NlI6KM7:TR?= MkDXV2FPT0WU
KU-19-19 NFfKcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITvNnlKSzVyPUOuNVcxOzRizszN MlvOV2FPT0WU
COLO-741 NFzGSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfWc41iUUN3ME2zMlE5Pjd|IN88US=> MWPTRW5ITVJ?
HSC-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWToWpBOUUN3ME2zMlI{OTVzIN88US=> MnmxV2FPT0WU
SN12C M1f1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjVNpRiUUN3ME2zMlI1PzBzIN88US=> M2f3d3NCVkeHUh?=
786-0 MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTNwMkeyOFMh|ryP NYLhZmgxW0GQR1XS
GAK MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLlTWM2OD1|LkOyOVYyKM7:TR?= NX7pSoNRW0GQR1XS
PANC-03-27 NWLEOoNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTNwM{WwOFUh|ryP NIDIWI9USU6JRWK=
CTB-1 M3zsPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLSTWM2OD1|LkS3NFQ4KM7:TR?= MlfzV2FPT0WU
A427 MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof3TWM2OD1|LkW5OVU3KM7:TR?= NVn2PZJmW0GQR1XS
EGI-1 NGrPdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HSNmlEPTB;Mz62NFU5OyEQvF2= M370fXNCVkeHUh?=
U-2-OS NETmSXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPFUWZKSzVyPUOuOlczPTZizszN MYnTRW5ITVJ?
NCI-SNU-5 M1LT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzvSFJKSzVyPUOuOlc4OyEQvF2= NF62folUSU6JRWK=
SK-LU-1 M2H2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\0ZmlEPTB;Mz62PFc6QCEQvF2= NInkVHdUSU6JRWK=
697 NV3UcY1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTNwNkm2NFMh|ryP MmG2V2FPT0WU
HPAF-II M3nrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTNwN{W0PUDPxE1? NWrkT3ptW0GQR1XS
NCI-H2087 NX7UVXVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTNwOES2O|Ih|ryP MkXRV2FPT0WU
SK-MEL-3 MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHSW2pkUUN3ME2zMlg2OTV2IN88US=> NWjtRYZVW0GQR1XS
CGTH-W-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTNwOEW3NlUh|ryP MYDTRW5ITVJ?
8505C MlvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPpS4tKSzVyPUOuPVAxPzhizszN NFrGPFZUSU6JRWK=
GAMG NXy2dJFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXndXBKSzVyPUSuNFI{PzdizszN NFqwfJNUSU6JRWK=
SW626 M1jCbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3n6ZWlEPTB;ND6wOFQ5KM7:TR?= MoPUV2FPT0WU
CAL-62 NE[zOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH73e|lKSzVyPUSuNFc1OyEQvF2= NYW5W49PW0GQR1XS
MHH-PREB-1 M1LlUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfLTWM2OD12LkGyNVEyKM7:TR?= M{\wV3NCVkeHUh?=
RPMI-7951 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPvTWM2OD12LkK1OVg6KM7:TR?= MUTTRW5ITVJ?
HOP-92 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\mR|FlUUN3ME20MlI2PjdizszN NVPoVFloW0GQR1XS
MDA-MB-231 MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTRwMkmyNlMh|ryP NIP4S5VUSU6JRWK=
LAN-6 NXfTfWtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LZW2lEPTB;ND6zNVY{PyEQvF2= NFPXU5ZUSU6JRWK=
ALL-PO M{H2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[5[HdKSzVyPUSuN|YyPTZizszN MYfTRW5ITVJ?
HH NVrTZ3IxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTRwNEG1PVch|ryP MWHTRW5ITVJ?
IGROV-1 NF7KT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTRwNEWxO|Eh|ryP MX;TRW5ITVJ?
NCI-H358 MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLad3lLUUN3ME20MlQ2Ozh3IN88US=> MVHTRW5ITVJ?
NB5 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEmzNXpKSzVyPUSuOlA{PjlizszN M4j2U3NCVkeHUh?=
NCI-H747 NY\IbplVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13wfGlEPTB;ND62PFgxPyEQvF2= MkDLV2FPT0WU
NH-12 NWfBdFRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWC3e4prUUN3ME20MlcyPjJ3IN88US=> NFTsUopUSU6JRWK=
LB1047-RCC NWm2TXltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn0bmp2UUN3ME20Mlc{QDF3IN88US=> MWPTRW5ITVJ?
EFO-27 NHq2WnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTRwN{i2Olch|ryP MYjTRW5ITVJ?
EPLC-272H NFXuSGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPJTWM2OD12Lkm5OlY6KM7:TR?= NHewcmtUSU6JRWK=
CAL-54 NXHhXVBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWW4UXJrUUN3ME21MlAzPjl3IN88US=> MnHkV2FPT0WU
H4 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvueJhKSzVyPUWuNFQzPTVizszN NH76RlNUSU6JRWK=
MOLT-13 M3TiOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEW2NGZKSzVyPUWuNFY4PzZizszN MUDTRW5ITVJ?
CAL-33 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUKySlZ4UUN3ME21MlEzOzF5IN88US=> NEX3VmVUSU6JRWK=
23132-87 NX\nWHFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTVwMU[4O|Ih|ryP NFXOd2dUSU6JRWK=
UM-UC-3 M3\sUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmW5TWM2OD13LkG4NFQ4KM7:TR?= Ml;aV2FPT0WU
HuH-7 MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTVwMkexOFch|ryP NFrMUnFUSU6JRWK=
BCPAP NITR[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1KxW2lEPTB;NT6zNlk3QSEQvF2= MYnTRW5ITVJ?
AsPC-1 M{fjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M16xN2lEPTB;NT6zOlc3OyEQvF2= MYPTRW5ITVJ?
NCI-H1155 NUPu[GFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\pTWM2OD13LkSwNFUyKM7:TR?= MXfTRW5ITVJ?
GT3TKB M4C0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LHRmlEPTB;NT60OlU6QCEQvF2= MX;TRW5ITVJ?
HCC2998 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPBOm5qUUN3ME21MlQ6OTB7IN88US=> M4\pUnNCVkeHUh?=
NUGC-3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDHfplLUUN3ME21MlQ6OzB{IN88US=> NInTSXRUSU6JRWK=
Hs-578-T MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoCzTWM2OD13LkWzO|k1KM7:TR?= NYPBdGE2W0GQR1XS
FADU NYmwWo5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XhcGlEPTB;NT61OVczPiEQvF2= MmnsV2FPT0WU
NBsusSR MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XJc2lEPTB;NT61O|E2PSEQvF2= M3fmVXNCVkeHUh?=
ME-180 NIPjWIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TkWmlEPTB;NT61PFA6OiEQvF2= M4TvUXNCVkeHUh?=
SW1710 NVXle3FNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTVwNkG2OVQh|ryP NYLofFdQW0GQR1XS
HuP-T3 M4\JPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmWwTWM2OD13Lk[yNFI6KM7:TR?= MY\TRW5ITVJ?
HOS MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjUTWM2OD13Lk[yPVI{KM7:TR?= M37Sd3NCVkeHUh?=
PA-1 NWroTm9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\neWlEPTB;NT62OFI3PSEQvF2= MWLTRW5ITVJ?
LU-99A MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEL2PVFKSzVyPUWuOlY1PTFizszN M{fGd3NCVkeHUh?=
RS4-11 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3hTWM2OD13Lk[2O|c2KM7:TR?= Mn;VV2FPT0WU
TE-8 NWLDWZhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;LPFZiUUN3ME21MlY5PTN5IN88US=> NUnRV2JLW0GQR1XS
RERF-LC-MS MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7ETIJKUUN3ME21MlY5QDB|IN88US=> M3nCcHNCVkeHUh?=
MEL-JUSO NIXGVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LVWmlEPTB;NT63N|c5KM7:TR?= M2XseXNCVkeHUh?=
SK-MES-1 NWjBXYdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTVwOEO1Nlgh|ryP M4HaeXNCVkeHUh?=
D-263MG MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\lc2lEPTB;NT64PFM2OSEQvF2= M4rNXnNCVkeHUh?=
NB10 MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXrTWM2OD13Lki5OFYh|ryP MX3TRW5ITVJ?
SK-HEP-1 NEPk[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTVwOUO0O|Eh|ryP Mkj5V2FPT0WU
HT-29 MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13yS2lEPTB;NT65PFEyQCEQvF2= NHPZfnZUSU6JRWK=
KYSE-140 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL6RWdKSzVyPU[uNFIyQDJizszN MYTTRW5ITVJ?
NCI-H1666 Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTZwMEi0OlEh|ryP MnP3V2FPT0WU
NCI-H1304 M3SyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\TbnM{UUN3ME22MlE6QTRizszN NXjsPIh3W0GQR1XS
RPMI-8866 M4rrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfjTWM2OD14LkKxN|E{KM7:TR?= M33qXHNCVkeHUh?=
MV-4-11 NYroPVV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTERXlRUUN3ME22MlI{OTl7IN88US=> NFy2PINUSU6JRWK=
A431 NWPJUlBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPPZ4VtUUN3ME22MlI1Ojl4IN88US=> NGLiVpZUSU6JRWK=
PANC-10-05 M{j3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTZwMkizOlMh|ryP M2HDbHNCVkeHUh?=
TK10 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HnfWlEPTB;Nj6zNlYxPCEQvF2= NX7PPJplW0GQR1XS
NCI-H1975 M{L3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHNfpdKSzVyPU[uOFczOTVizszN MUfTRW5ITVJ?
A172 NIHydINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLVTWM2OD14LkS5NVc3KM7:TR?= NEjaVYxUSU6JRWK=
D-566MG NIH0SVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXjTWM2OD14LkW0N|A{KM7:TR?= NFfORo5USU6JRWK=
NCI-H2122 MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPSTWM2OD14Lk[xOVI5KM7:TR?= M1zUTHNCVkeHUh?=
COR-L105 M4LQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TjOGlEPTB;Nj62OVI4PSEQvF2= NVTjd5k5W0GQR1XS
AN3-CA Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTnTWM2OD14Lk[4OlQyKM7:TR?= Mo\RV2FPT0WU
Calu-6 NELtNldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:5TWM2OD14Lke5Olk5KM7:TR?= MmXxV2FPT0WU
HCT-116 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGmyZlJKSzVyPU[uPFEzPjRizszN NF\SVpFUSU6JRWK=
MHH-NB-11 NUTWXXdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF21PIJKSzVyPU[uPFUxODJizszN MkGxV2FPT0WU
MFE-280 NFu5WFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHC[opKSzVyPU[uPFU6QDNizszN NWHDUm51W0GQR1XS
SW1088 MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXCZVVKSzVyPU[uPVE6OTNizszN M2TNSXNCVkeHUh?=
SW48 NWe3b2lTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Gw[2lEPTB;Nj65OFUyKM7:TR?= NILmT3RUSU6JRWK=
HuCCT1 M4O4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX2yTYNZUUN3ME23MlAyODN5IN88US=> MYHTRW5ITVJ?
ACHN MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXUTWM2OD15LkCyPVQ{KM7:TR?= NYPVNotyW0GQR1XS
8305C NF3MOlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfVTWM2OD15LkC5PVk2KM7:TR?= Mk\ZV2FPT0WU
DoTc2-4510 M4HQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDrR4dYUUN3ME23MlEzOTVizszN M3[xVHNCVkeHUh?=
COR-L23 NX3kVnVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37ue2lEPTB;Nz6yOFQzKM7:TR?= NH73dINUSU6JRWK=
SK-MEL-30 NHzLUoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\aU4xKSzVyPUeuNlUxQDNizszN NID3OnFUSU6JRWK=
BE-13 NIq4U|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTdwM{O4N|Qh|ryP NFzCVFJUSU6JRWK=
GR-ST M1\G[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHQTXpKSzVyPUeuOFAyPzRizszN NGT0SFZUSU6JRWK=
LU-135 Mk\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTdwNUW5N|kh|ryP NWXaSmk1W0GQR1XS
U-266 NGjDfHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnLTWM2OD15LkW2Nlg3KM7:TR?= MYrTRW5ITVJ?
NCI-H1355 Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEiwOpVKSzVyPUeuOVg3OzVizszN NVX3NphHW0GQR1XS
NB14 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTdwNk[2OFIh|ryP MYrTRW5ITVJ?
SCC-25 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPyeppKSzVyPUeuO|A6KM7:TR?= NGHhSIFUSU6JRWK=
COLO-678 NIXPOJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTdwN{GwO|Yh|ryP Ml3wV2FPT0WU
TGBC1TKB NXnReFgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTdwOEmzPVgh|ryP M4WxSHNCVkeHUh?=
IST-MEL1 NVq2eYJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLxTWM2OD16LkCwOFA3KM7:TR?= NGX1[ohUSU6JRWK=
ECC10 MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvpTZFKSzVyPUiuNFM{QTVizszN M4\oOnNCVkeHUh?=
EW-16 NFP2XXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvETWM2OD16LkC4OFQ2KM7:TR?= M3HxSXNCVkeHUh?=
DOHH-2 NVjUd5JuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfrTWM2OD16LkKwNFk2KM7:TR?= M4TiXnNCVkeHUh?=
NCI-H1581 NXLPe5VLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PiUWlEPTB;OD6yOlMzOyEQvF2= M3PQNXNCVkeHUh?=
TE-5 MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jmdWlEPTB;OD60NlQzQSEQvF2= MUDTRW5ITVJ?
CAKI-1 NXe1NndGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4H3WWlEPTB;OD61O|IzOiEQvF2= MnL0V2FPT0WU
A673 NE\aZZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\OTWM2OD16Lk[zNlAzKM7:TR?= MYLTRW5ITVJ?
CAL-12T MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfsNIRKSzVyPUiuOlU4PTNizszN M4[2eHNCVkeHUh?=
DBTRG-05MG MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7TN2pKSzVyPUiuO|Q5PTlizszN NU\zPYlOW0GQR1XS
SK-N-FI M2PTUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjPXZpRUUN3ME24MlgyOzd7IN88US=> NXrOU5Y1W0GQR1XS
K-562 M{LzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;2S3ZkUUN3ME24Mlg{QTV5IN88US=> NEi0TVJUSU6JRWK=
SBC-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW2TWM2OD16Lki2OlQ2KM7:TR?= M{TuTXNCVkeHUh?=
ES4 M4XRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRThwOE[4PFQh|ryP M4HSUHNCVkeHUh?=
MS-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;w[oNDUUN3ME24Mlg4PTF5IN88US=> NVnNbI15W0GQR1XS
RKO NWLyPINVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRThwOEmwOVch|ryP MWPTRW5ITVJ?
NCI-H1693 M1;I[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfKTWM2OD16LkmyNVch|ryP NX;mW5FMW0GQR1XS
SW954 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfMOWdjUUN3ME24Mlk3QTd6IN88US=> M{\NWnNCVkeHUh?=
SK-UT-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRThwOUe2PFMh|ryP M3\Id3NCVkeHUh?=
T98G NVr5TFdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zGdGlEPTB;OD65PVg1PiEQvF2= MWTTRW5ITVJ?
NCI-H2126 NGLoTZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzoTWM2OD17LkCwPFI3KM7:TR?= MVvTRW5ITVJ?
TE-12 NFXHTFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXiNYdKSzVyPUmuNFM{PjdizszN MXHTRW5ITVJ?
DK-MG MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTlwMkGxPVEh|ryP NHT1ZmlUSU6JRWK=
MEG-01 MlTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnHTWM2OD17LkK0PVMyKM7:TR?= MmC4V2FPT0WU
HCC1937 NIDNTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jiTmlEPTB;OT6yPVA6OSEQvF2= Ml7kV2FPT0WU
MKN45 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\mdGlEPTB;OT60OVA3PSEQvF2= NWm2fZpsW0GQR1XS
NCI-H1792 M2HSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfsTWM2OD17LkS1NlE6KM7:TR?= NGTJNJlUSU6JRWK=
SW1417 NVPkOGFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTUTWM2OD17LkW2PFM4KM7:TR?= M3\oUHNCVkeHUh?=
639-V MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\kTWM2OD17Lk[0N|g5KM7:TR?= MVLTRW5ITVJ?
P30-OHK NYLwZpFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;LOGFpUUN3ME25MlY2OzF4IN88US=> M4j5VHNCVkeHUh?=
YKG-1 NWnKfHZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjYWmg6UUN3ME25Mlc2ODN|IN88US=> MljvV2FPT0WU
KGN MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TUfGlEPTB;OT64N|c6PSEQvF2= MV;TRW5ITVJ?
MSTO-211H NYHNNVZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUS5SoxZUUN3ME25Mlk2PTJ7IN88US=> MoPMV2FPT0WU
NCI-H1573 NIjNd4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFyLkG1O|Qh|ryP MmrUV2FPT0WU
NCI-H720 M37tdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrXPYRKSzVyPUGwMlE6QDlizszN NILyOIxUSU6JRWK=
KARPAS-45 NGL5NXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7xTWM2OD1zMD6yO|k2KM7:TR?= NG\VVWJUSU6JRWK=
MDA-MB-175-VII NIfJVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGn6SlZKSzVyPUGwMlQ5KM7:TR?= NHfPeIpUSU6JRWK=
SK-NEP-1 NGPRNo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nn[GlEPTB;MUCuOFk5OSEQvF2= NFXvNFFUSU6JRWK=
MKN28 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfSZotKSzVyPUGwMlUyQCEQvF2= M4fVdXNCVkeHUh?=
KYSE-520 MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHqTWM2OD1zMD61NkDPxE1? MUTTRW5ITVJ?
KE-37 NWPQSGc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDNd3JxUUN3ME2xNE42Ojd{IN88US=> M{Xs[nNCVkeHUh?=
VA-ES-BJ MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Pl[WlEPTB;MUCuOVY4KM7:TR?= NVLrfZVtW0GQR1XS
CCRF-CEM MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTiTWM2OD1zMD61Olg1KM7:TR?= NXPPS5U{W0GQR1XS
GMS-10 NVPSV5RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFyLk[wPVQh|ryP MmjMV2FPT0WU
NCI-H1623 Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfkcXpKSzVyPUGwMlY{PzlizszN MoDFV2FPT0WU
NEC8 MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnruTWM2OD1zMD63O|c{KM7:TR?= M4r6OnNCVkeHUh?=
MOLT-16 NHf3cVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\aTWM2OD1zMD64NVE{KM7:TR?= MnzaV2FPT0WU
DJM-1 Mlq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3UZllKSzVyPUGxMlA{PzlizszN MV7TRW5ITVJ?
U251 NHv0XJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfkZYFOUUN3ME2xNU4xPDJizszN Ml:3V2FPT0WU
SBC-5 MlSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTGNotKSzVyPUGxMlE1PjdizszN NH\BXoNUSU6JRWK=
SW756 NFvkVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDaU4E4UUN3ME2xNU4zOTV2IN88US=> MX3TRW5ITVJ?
KS-1 NGLBZ|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTETWM2OD1zMT6yOlE6KM7:TR?= NVTE[HdoW0GQR1XS
SF295 M3K2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF64R|FKSzVyPUGxMlMyODRizszN MULTRW5ITVJ?
YH-13 MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHsZ3p5UUN3ME2xNU4{OjZ5IN88US=> NUjubGNrW0GQR1XS
SW837 NYm3cnZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\mbYM1UUN3ME2xNU4{PTB4IN88US=> MV\TRW5ITVJ?
KYSE-450 NEfjd|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrwV2FKSzVyPUGxMlQxPTdizszN NEK3SZNUSU6JRWK=
KYSE-180 M4Tj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXmxR3Y{UUN3ME2xNU41QDJizszN MkLZV2FPT0WU
S-117 NIHTV|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWK4[odSUUN3ME2xNU41QDl4IN88US=> NYqyTFRPW0GQR1XS
KOSC-2 NUjqepF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfNVJpKSzVyPUGxMlYzOjJizszN NWLXSZZiW0GQR1XS
KYSE-270 M17uU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDGTWM2OD1zMT64O|Q2KM7:TR?= M2jYPHNCVkeHUh?=
D-336MG MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XQTWlEPTB;MUGuPVA4PSEQvF2= M2fZOnNCVkeHUh?=
KALS-1 NYLtboRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvoOI5KSzVyPUGyMlAxOTZizszN NXuwTpN4W0GQR1XS
LB373-MEL-D NIXWdolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7WZXNKSzVyPUGyMlA2OzNizszN MYXTRW5ITVJ?
HLE MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF{LkC1PFUh|ryP NFvVOmRUSU6JRWK=
SJSA-1 M2fOe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTSSFNKSzVyPUGyMlA4OzVizszN NWixSplVW0GQR1XS
SW1990 MoDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4e2TGlEPTB;MUKuNFkyOSEQvF2= NVj1TGpGW0GQR1XS
NOS-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDSW3BGUUN3ME2xNk4yOzV{IN88US=> NHi0dJNUSU6JRWK=
GI-ME-N MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfuTWM2OD1zMj6yNVY{KM7:TR?= MnvCV2FPT0WU
NCI-H1703 M4\qRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfFTlN5UUN3ME2xNk4zPjF4IN88US=> M{HncHNCVkeHUh?=
ES7 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTF{LkK3NlQh|ryP MVXTRW5ITVJ?
KYSE-510 NHjETYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PESWlEPTB;MUKuOVA4QSEQvF2= NUD5epRIW0GQR1XS
BHY NUDjUYpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4K2bmlEPTB;MUKuOVMxPyEQvF2= NFHrd5ZUSU6JRWK=
TCCSUP NIDNW4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTOWVNKSzVyPUGyMlU4PTdizszN NH;h[WVUSU6JRWK=
HSC-2 NWXRe5VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrz[G5KSzVyPUGyMlU6QTZizszN NF;KVo9USU6JRWK=
BEN NEG3T3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInCUoVKSzVyPUGyMlYyPDNizszN NVL0dHNYW0GQR1XS
769-P M2LYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzsWpJKSzVyPUGyMlc6OjRizszN NFnmPGJUSU6JRWK=
HT M3S3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTF{LkizOFYh|ryP NHrK[FhUSU6JRWK=
LXF-289 MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTF{Lkm1N|Eh|ryP NV2wW3FLW0GQR1XS
OVCAR-3 NYTVZ4xCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fYVGlEPTB;MUKuPVU3PyEQvF2= NX\pU4FSW0GQR1XS
ATN-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3rRnlCUUN3ME2xN{4xOTh2IN88US=> NFrYWppUSU6JRWK=
8-MG-BA MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLqe2FGUUN3ME2xN{4xPDV3IN88US=> M1G4cHNCVkeHUh?=
SW13 NVrNeGdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXjTWM2OD1zMz6xNVY2KM7:TR?= NV33N2NtW0GQR1XS
NCI-H1092 NFvJXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVniPZlIUUN3ME2xN{4yPjJizszN MkPkV2FPT0WU
OAW-42 NHH3bHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH2[3llUUN3ME2xN{4yQTN5IN88US=> MVTTRW5ITVJ?
NCI-H2452 MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL2ZpRuUUN3ME2xN{4zOTd3IN88US=> Mn:0V2FPT0WU
CAPAN-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLz[45KSzVyPUGzMlU2OTRizszN M{nidHNCVkeHUh?=
NCI-H2009 MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnHTWM2OD1zMz61PVE6KM7:TR?= NFrBcGhUSU6JRWK=
SF268 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTF|Lk[zNlYh|ryP M1\KZXNCVkeHUh?=
GCIY M4jsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXiS|lKSzVyPUGzMlY6OjdizszN MkPhV2FPT0WU
OS-RC-2 MorTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T2fmlEPTB;MUOuPVUxOSEQvF2= MnHzV2FPT0WU
GCT MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PVS2lEPTB;MUOuPVY6PyEQvF2= NUPiVXU2W0GQR1XS
NB17 NWX1NlVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\xZWlEPTB;MUSuNFg2KM7:TR?= MlznV2FPT0WU
NCI-H2030 MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LR[mlEPTB;MUSuNVQ3PSEQvF2= NUHmVow4W0GQR1XS
HC-1 MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITNbm9KSzVyPUG0MlIxQDdizszN MkP3V2FPT0WU
QIMR-WIL NXnae3dST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;qTWM2OD1zND6zOFEzKM7:TR?= MV3TRW5ITVJ?
Capan-2 MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTF2LkO3NVQh|ryP MmPjV2FPT0WU
BALL-1 NFvDelJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[5WZVKSzVyPUG0MlQ3PjVizszN MmnnV2FPT0WU
LS-1034 Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXzZ5JmUUN3ME2xOE43OTV{IN88US=> MVjTRW5ITVJ?
U-118-MG M1\EVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2q0UWlEPTB;MUSuOlMyKM7:TR?= MnfMV2FPT0WU
NCI-H630 NGjvdmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:5[GlEPTB;MUSuOlU3QCEQvF2= MUfTRW5ITVJ?
OVCAR-8 NHjGV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;4TWM2OD1zND63NlAyKM7:TR?= MYDTRW5ITVJ?
NCI-H2347 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3TTWM2OD1zND64NlMh|ryP NE\zOYFUSU6JRWK=
BT-549 Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HIdGlEPTB;MUSuPFI5PCEQvF2= MVLTRW5ITVJ?
LB831-BLC M1HKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;vTWM2OD1zND64PVM1KM7:TR?= MoK4V2FPT0WU
NCI-H661 NV\Senl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvUPIdKSzVyPUG0Mlk2QSEQvF2= M4fM[HNCVkeHUh?=
MKN7 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7CTWM2OD1zNT6wNFk{KM7:TR?= MlXPV2FPT0WU
U-87-MG NHLjT5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPvTWM2OD1zNT6wPFk4KM7:TR?= NHzLPXZUSU6JRWK=
OVCAR-4 NHjTb3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XERmlEPTB;MUWuNVQzPCEQvF2= MnXBV2FPT0WU
OE33 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTF3LkG3NVEh|ryP MoD2V2FPT0WU
EC-GI-10 NWrMT4dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL3TWM2OD1zNT6yN|U4KM7:TR?= NGXQSGxUSU6JRWK=
AM-38 NYn0fWk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\UfnhKSzVyPUG1MlI4OTdizszN NVXBXW9OW0GQR1XS
NCI-H1563 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF3LkO0PUDPxE1? NF;veldUSU6JRWK=
SCC-4 M2\NPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXNT2ZKSzVyPUG1MlQyODNizszN M1HVdHNCVkeHUh?=
Detroit562 Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrl[nFjUUN3ME2xOU41PTR5IN88US=> MlKyV2FPT0WU
PC-14 NYKzcpVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH23eoVKSzVyPUG1MlQ5PjZizszN NFHrT4VUSU6JRWK=
ES3 M1GxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rvTWlEPTB;MUWuOVM3KM7:TR?= MlXYV2FPT0WU
OCI-AML2 NFHp[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXIXYtMUUN3ME2xOU44PjF2IN88US=> NWL5TWFxW0GQR1XS
LU-134-A MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF3LkmwNVgh|ryP MlG2V2FPT0WU
SAS MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIn3O|ZKSzVyPUG1Mlk{PzNizszN NVfFPXRHW0GQR1XS
TGBC11TKB NFPIOYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTF3Lkm0NVQh|ryP NFXiVG9USU6JRWK=
HOP-62 NIDoNZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIqwbJNKSzVyPUG1Mlk2QTdizszN MlXqV2FPT0WU
G-401 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr4SJU4UUN3ME2xOU46PjR7IN88US=> Mmj2V2FPT0WU
NCI-H28 M1vHZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGK4clhKSzVyPUG2MlA5PTZizszN M37rcHNCVkeHUh?=
A204 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEn4N4hKSzVyPUG2MlIxODZizszN MUHTRW5ITVJ?
NCI-H1299 NGrLUJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;ySYlKSzVyPUG2MlIzQTFizszN Mn;PV2FPT0WU
VMRC-RCZ NF;VUHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTIUoFKSzVyPUG2MlI2QTJizszN MVvTRW5ITVJ?
BxPC-3 NGHpWIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPTR|NSUUN3ME2xOk4zQDV4IN88US=> M4C5enNCVkeHUh?=
NCI-H2228 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV75T2Z{UUN3ME2xOk42OTV6IN88US=> NH\0U5RUSU6JRWK=
NCI-H23 NVjlU5RjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfaOVRKSzVyPUG2MlYxPzhizszN MkW0V2FPT0WU
NKM-1 MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\iN2lEPTB;MUeuNFE5QSEQvF2= NGX3W5FUSU6JRWK=
KYSE-70 Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\wTWM2OD1zNz6yPFkh|ryP NUDFPW5vW0GQR1XS
BB49-HNC NFTtWZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nzXmlEPTB;MUeuOVY5PiEQvF2= NVXzfJpSW0GQR1XS
SCC-15 M2T3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXxTWM2OD1zNz64OFc{KM7:TR?= MYDTRW5ITVJ?
D-247MG MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTF5LkmyOFch|ryP M3\CNXNCVkeHUh?=
BB30-HNC NV71W4RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L3dmlEPTB;MUiuNFMyQCEQvF2= M3juU3NCVkeHUh?=
CAL-85-1 NEXUU2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF6LkG4NFkh|ryP MVvTRW5ITVJ?
HT-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTF6LkO5O|ch|ryP M2XSdHNCVkeHUh?=
KYSE-410 M{juemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfCTWM2OD1zOD60OVc4KM7:TR?= NHm3VoFUSU6JRWK=
SW982 NW\oWGw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;LS3lKSzVyPUG4MlU3PDlizszN NGexW5pUSU6JRWK=
SW962 MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7mOlZiUUN3ME2xPE42PzB{IN88US=> MVLTRW5ITVJ?
Ramos-2G6-4C10 NY\yRYNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DDdWlEPTB;MUiuOVkzPyEQvF2= NXjPcHJsW0GQR1XS
OC-314 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\2TWM2OD1zOD63N|g1KM7:TR?= M1;TRnNCVkeHUh?=
LS-123 NYHG[|YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjvdWdKSzVyPUG4Mlc6ODFizszN NWPGRmdVW0GQR1XS
D-502MG NUXie5RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfTTWM2OD1zOD64NVM6KM7:TR?= M2HxTnNCVkeHUh?=
RO82-W-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HGO2lEPTB;MUiuPFI5QCEQvF2= NX[wNFl5W0GQR1XS
HuO9 NVexVXNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDlTWM2OD1zOT6xN|c6KM7:TR?= MX7TRW5ITVJ?
ETK-1 M{HzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPWdXp3UUN3ME2xPU4yQDJ5IN88US=> M1LrOnNCVkeHUh?=
SNU-387 NVT2U3RxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;HU2M4UUN3ME2xPU4yQDh7IN88US=> MWLTRW5ITVJ?
SW1573 NX\SPZBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LQd2lEPTB;MUmuNVk3QSEQvF2= MojqV2FPT0WU
NTERA-S-cl-D1 NX\JbGhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:1XlVKSzVyPUG5MlIxODdizszN MlKyV2FPT0WU
SF126 NVOyTFBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1z2bWlEPTB;MUmuN|UxOiEQvF2= MW\TRW5ITVJ?
Calu-3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIn6TFJKSzVyPUG5MlQzOzdizszN NUTkN|VKW0GQR1XS
NCI-H1048 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrPcHFKSzVyPUKwMlMzPjZizszN NYLiSY92W0GQR1XS
NCI-H226 NFr4N3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\IdYNKSzVyPUKwMlQ{QTlizszN MUnTRW5ITVJ?
FTC-133 NGrTTpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LCNWlEPTB;MkCuOFcxOyEQvF2= MXnTRW5ITVJ?
SF539 Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDtdJBKSzVyPUKwMlUyPzJizszN NFLmSI5USU6JRWK=
TE-6 M4LMUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJyLkiwOlch|ryP NEfvflhUSU6JRWK=
UMC-11 NVPlXXFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXMRpVKSzVyPUKwMlkyPjRizszN M3KxfHNCVkeHUh?=
Becker NV2zcGVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTJzLkGxNVgh|ryP NWPyVZQzW0GQR1XS
KP-4 MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LnXGlEPTB;MkGuNVE6PiEQvF2= MWXTRW5ITVJ?
ChaGo-K-1 NWH4SYU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJzLkO2Nlch|ryP NYDrdotrW0GQR1XS
CFPAC-1 M1HHZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJzLkO4OVgh|ryP NUDa[IVkW0GQR1XS
A498 NXu1fHZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPOVnlDUUN3ME2yNU42OzF{IN88US=> MXTTRW5ITVJ?
NCI-H1755 NWjnbG5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrVbIxMUUN3ME2yNU43PzRzIN88US=> MXPTRW5ITVJ?
TI-73 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1u5eWlEPTB;MkKuN|I5KM7:TR?= MVvTRW5ITVJ?
NCI-H441 NH7XN|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTJ{LkW2PFkh|ryP MXrTRW5ITVJ?
CaR-1 NI\ESWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;FTWM2OD1{Mz6wNlE{KM7:TR?= MYDTRW5ITVJ?
HCC1806 MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L6OmlEPTB;MkOuNFU5OyEQvF2= MXrTRW5ITVJ?
SNU-449 NUC0VnppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\xcHJKSzVyPUKzMlMzQSEQvF2= NYnoelNrW0GQR1XS
EKVX MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXJTWM2OD1{Mz6zPVA6KM7:TR?= MmXEV2FPT0WU
DMS-114 M3\4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJ|LkW3OlUh|ryP NUfaeXhQW0GQR1XS
A704 M2mx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;LTWM2OD1{Mz62NVA{KM7:TR?= MUfTRW5ITVJ?
LC-2-ad NEnTc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJ|Lk[xOFch|ryP NFrIXIxUSU6JRWK=
VM-CUB-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4n5NWlEPTB;MkOuO|M1OSEQvF2= Ml\jV2FPT0WU
PC-3 M13SXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu2S|ZtUUN3ME2yOE4xPTJ4IN88US=> MlXoV2FPT0WU
HEL MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJ2LkC4OlUh|ryP NUXESIhoW0GQR1XS
ABC-1 MojjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTIRZNDUUN3ME2yOE4zPzJ7IN88US=> Ml:3V2FPT0WU
COLO-680N NV\4[ZJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PUUWlEPTB;MkSuOFc3PCEQvF2= M{m2SXNCVkeHUh?=
MZ1-PC NX62ZWs4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4q1UGlEPTB;MkSuOlg4KM7:TR?= NEPmSpNUSU6JRWK=
NCI-H69 MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHhTWM2OD1{ND63N|U1KM7:TR?= NYjDZ5FNW0GQR1XS
TE-1 M1jDT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJ3LkC0PVkh|ryP M3rr[nNCVkeHUh?=
EW-3 M2XndGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlm3TWM2OD1{NT6xNVMh|ryP Mk\pV2FPT0WU
PANC-08-13 MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJ3LkixNFMh|ryP NIOwWWpUSU6JRWK=
NMC-G1 M2Xu[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\Xd4NKSzVyPUK2MlAxQDhizszN NIfXNI9USU6JRWK=
BT-20 NVzURlRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrTWlFKSzVyPUK2MlQ2PDNizszN Mln6V2FPT0WU
TGBC24TKB MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDQcmh4UUN3ME2yOk44OzNzIN88US=> MXrTRW5ITVJ?
TE-11 NXO4dJRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HpOmlEPTB;Mk[uPVg6PSEQvF2= MkHGV2FPT0WU
ESS-1 NXTDXotXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJ5LkOyNVYh|ryP M4\HRXNCVkeHUh?=
JVM-3 M2D2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTJ5Lk[0O|Uh|ryP NX2ydJlDW0GQR1XS
C3A NHjMWpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWm3fHlJUUN3ME2yO{45PDl4IN88US=> NEPiW2RUSU6JRWK=
MDA-MB-157 NFPKOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TR[mlEPTB;MkeuPFc2OyEQvF2= NVzWWmhnW0GQR1XS
KLE MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDGR2hSUUN3ME2yPE4yODV6IN88US=> M{HDcnNCVkeHUh?=
ES1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJ6LkG4N|gh|ryP MUXTRW5ITVJ?
CAL-120 NIrDVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEW0enJKSzVyPUK4MlM6QTlizszN M1L4[HNCVkeHUh?=
NCI-N87 M{L5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX2TWM2OD1{OD61NVA2KM7:TR?= M{DHdHNCVkeHUh?=
RPMI-8226 M{jufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHGxSYtKSzVyPUK5MlE5PDNizszN NFXIVlRUSU6JRWK=
COR-L88 NUDBN2M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Lm[mlEPTB;MkmuNlQyQSEQvF2= MlPnV2FPT0WU
UACC-893 NFTFTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXf3OI5oUUN3ME2yPU4{OTN5IN88US=> NWS1SlFmW0GQR1XS
C8166 NWLNRY1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\HTWM2OD1{OT65PVk3KM7:TR?= M4K0S3NCVkeHUh?=
J82 NGjxemFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTNyLkixOFch|ryP NW\tRVkyW0GQR1XS
PFSK-1 M3LFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3q5WWlEPTB;M{GuNFY2QSEQvF2= NVzUU|lFW0GQR1XS
COLO-684 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvkTWM2OD1|MT60N|c1KM7:TR?= M17Sb3NCVkeHUh?=
CAL-72 M{XFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XkPWlEPTB;M{GuOVczQSEQvF2= MljqV2FPT0WU
SNB75 M4L5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjFSJpKSzVyPUOxMlg6PyEQvF2= NHHqd2xUSU6JRWK=
MDA-MB-415 NFfSZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\0TWxGUUN3ME2zNU46PzZ{IN88US=> M4\uNXNCVkeHUh?=
SiHa M13tZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nCUWlEPTB;M{KuOFcyOSEQvF2= NYjyT|Z[W0GQR1XS
NCI-H1648 MorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zFXGlEPTB;M{KuPVM1PSEQvF2= NHjxfo9USU6JRWK=
EFO-21 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX3TWM2OD1|Mz6wNFUh|ryP M1n3b3NCVkeHUh?=
HCC38 MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTubGVXUUN3ME2zN{4{QDRzIN88US=> MknxV2FPT0WU
IA-LM MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjnRlZlUUN3ME2zN{44QDh7IN88US=> NYm2VG11W0GQR1XS
CTV-1 MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\mRpBqUUN3ME2zN{46Pzh4IN88US=> NH3BXItUSU6JRWK=
NCI-H446 MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPOTWM2OD1|ND6yOlg6KM7:TR?= Moi0V2FPT0WU
IST-SL1 M{DmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvDTWM2OD1|ND63OFA5KM7:TR?= NFKybHVUSU6JRWK=
EW-22 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\hR3FKSzVyPUO0Mlc4PTlizszN M1;veHNCVkeHUh?=
JEG-3 M1zERWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfXblFSUUN3ME2zOk4yPzZ4IN88US=> NYHwVYp5W0GQR1XS
LU-65 MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTN4LkK5PFUh|ryP MoG4V2FPT0WU
NCI-H596 NXXrR2RYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkW5TWM2OD1|Nj65OVkyKM7:TR?= NXL0eWZwW0GQR1XS
KNS-81-FD NYTXdo9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XDb2lEPTB;M{euNVQ2KM7:TR?= M{DkfXNCVkeHUh?=
NCI-H1793 MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XTdmlEPTB;M{euO|A5PiEQvF2= NHztTpBUSU6JRWK=
NCI-H460 Mn6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTN6LkC4O|Mh|ryP NXXJNYhMW0GQR1XS
MPP-89 M2e2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjEUIhKSzVyPUO5MlU5QDZizszN MkDRV2FPT0WU
D-542MG NEXLSIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTN7Lki0N|Yh|ryP M4my[XNCVkeHUh?=
JAR NUX1ZVNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XJWWlEPTB;NECuOFcxPSEQvF2= NETiUHBUSU6JRWK=
NCI-H209 NGr4eI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTRyLk[3O{DPxE1? NXTvU2F{W0GQR1XS
G-402 MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXMTWM2OD12MT6zPVk{KM7:TR?= Mn;mV2FPT0WU
IST-MES1 MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2THWWlEPTB;NEKuNVk{PSEQvF2= NFHoXY1USU6JRWK=
Daoy NIS5OI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUW1R4ppUUN3ME20Nk42PDdzIN88US=> MnzHV2FPT0WU
EW-11 Mor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33QW2lEPTB;NEOuNVIyOSEQvF2= NGDUOmJUSU6JRWK=
Saos-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\zTnhKSzVyPUSzMlE2OzdizszN MlfrV2FPT0WU
no-10 M4fZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2riTmlEPTB;NEOuNVcxOiEQvF2= NHv3OZNUSU6JRWK=
HCC1395 NVzvWotrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4j6VGlEPTB;NEOuOFY1PCEQvF2= NWjn[pVQW0GQR1XS
HCE-4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzxTWM2OD12Mz63OlY1KM7:TR?= MYnTRW5ITVJ?
EW-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTR|LkiwOFkh|ryP NF7h[WdUSU6JRWK=
OCUB-M M12yN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUP3SYJOUUN3ME20OE4{PjN6IN88US=> M1yxXXNCVkeHUh?=
IGR-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\EUHBKSzVyPUS0MlQyOTVizszN NYL4N45PW0GQR1XS
NCI-H1838 NXPORlhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PUZ2lEPTB;NESuOFM1QSEQvF2= NUPlPGc2W0GQR1XS
NCI-H2405 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEiyS3dKSzVyPUS0MlU{PCEQvF2= Mor5V2FPT0WU
GB-1 NV;Ke3ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUG1N|EyUUN3ME20OE44PDZ|IN88US=> MWrTRW5ITVJ?
MG-63 NWDQTHhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjtOFhKSzVyPUS2MlA3QTZizszN M1vkcXNCVkeHUh?=
KP-N-YN MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\HeWlEPTB;NE[uOFY4QSEQvF2= NHfINIlUSU6JRWK=
no-11 NXLxdYttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXmd5ZOUUN3ME20O{4xOjR2IN88US=> M1zTTHNCVkeHUh?=
SW948 Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe2W5ZKSzVyPUS3MlM{PzdizszN MXLTRW5ITVJ?
CAMA-1 NVfBdGVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFX0TJhKSzVyPUS3MlM1OzhizszN Mle3V2FPT0WU
HCC1187 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DtZWlEPTB;NEeuOVEh|ryP M4XheHNCVkeHUh?=
D-392MG M1H0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTR5Lk[1NVYh|ryP NXP6PW57W0GQR1XS
647-V Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXWUFJKSzVyPUS5MlM1OTRizszN M4[4WHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. [1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. [2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. [5]

Protocol

Kinase Assay:

[2]

+ Expand

MEK1 Assay:

MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl2 /2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research:

[1]

+ Expand
  • Cell lines: Colon 26 carcinoma cells
  • Concentrations: 0.1-10 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are planted seeded in T-75 cm 2 flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: PTC cells in athymic mice
  • Formulation: Cremophor EL–95% ethanol (50:50) and dilutes with water
  • Dosages: 150 mg/kg
  • Administration: Orally twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 96 mg/mL (200.55 mM)
Ethanol 14 mg/mL (29.24 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol, pH 9
For best results, use promptly after mixing.
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 478.67
Formula

C17H14ClF2IN2O2

CAS No. 212631-79-3
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy PD184352 (CI-1040) | PD184352 (CI-1040) supplier | purchase PD184352 (CI-1040) | PD184352 (CI-1040) cost | PD184352 (CI-1040) manufacturer | order PD184352 (CI-1040) | PD184352 (CI-1040) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID